1. yl23455永利官网

    洞察市场格局
    解锁药品研发情报

    免费客服电话

    18983288589
    医药数据查询

    【ChiCTR2500102879】Taurine Or Placebo for Healthcare Workers: the TOP Healthcare workers' Bayesian Optimized Phase II randomised-controlled trial

    基本信息
    登记号

    ChiCTR2500102879

    试验状态

    尚未开始

    药物名称

    /

    药物类型

    /

    规范名称

    /

    首次公示信息日的期

    2025-05-21

    临床申请受理号

    /

    靶点

    /

    适应症

    None

    试验通俗题目

    Taurine Or Placebo for Healthcare Workers: the TOP Healthcare workers' Bayesian Optimized Phase II randomised-controlled trial

    试验专业题目

    Taurine Or Placebo for Healthcare Workers: the TOP Healthcare workers' Bayesian Optimized Phase II randomised-controlled trial

    申办单位信息
    申请人联系人
    申请人名称
    联系人邮箱
    联系人邮编

    联系人通讯地址
    临床试验信息
    试验目的

    To assess whether oral taurine supplementation will improve metabolic health of healthcare workers.

    试验分类
    试验类型

    随机平行对照

    试验分期

    其它

    随机化

    Randomization and data capture will be through the RedCap.

    盲法

    Everyone will be blinded to the study capsules - maybe except the company that manufactures the study capsules in Western Australia. Bottle will be labelled as A or B (with certain serial study number).

    试验项目经费来源

    Department internal funding

    试验范围

    /

    目标入组人数

    40

    实际入组人数

    /

    第一例入组时间

    2025-07-01

    试验终止时间

    2027-12-08

    是否属于一致性

    /

    入选标准

    Healthcare related workers who can read and understand English or Chinese translated version of the study questionnaires will be invited to participate including doctors, nurses, physiotherapists, dietitians, or research-related workers at the New Territories East Cluster Hospitals；

    排除标准

    (a)Are taking taurine prior to enrolment, (b) Have chronic renal disease (eGFR<30ml/min: as taurine can accumulate in renal failure) (c) Insulin-dependent diabetes mellitus (d) A bleeding disorder (e.g. platelet count < 100x10^9/L or treated with dual antiplatelet agents: as taurine has potential antiplatelet activity in vitro) (e) Received active chemo/immunotherapy < 30 days before enrolment or likely to receive such treatment during the study (f) Pregnant or planning to become pregnant；

    研究者信息
    研究负责人姓名
    试验机构

    The Chinese University of Hong Kong

    研究负责人电话
    研究负责人邮箱
    研究负责人邮编

    /

    联系人通讯地址

    The Chinese University of Hong Kong的其他临床试验

    更多

    最新临床资讯

    yl23455永利官网企业版
    50亿+条医药数据随时查
    7天免费试用
    体验产品